» Articles » PMID: 10510215

The Pharmacology of Bisphosphonates and New Insights into Their Mechanisms of Action

Overview
Date 1999 Oct 6
PMID 10510215
Citations 52
Authors
Affiliations
Soon will be listed here.
Abstract

Bisphosphonates are chemically stable analogs of inorganic pyrophosphate, which are resistant to breakdown by enzymatic hydrolysis. The biological effects of bisphosphonates on calcium metabolism were originally ascribed to their physico-chemical effects on hydroxyapatite crystals. Although such effects may contribute to their overall action, their effects on cells are probably of greater importance, particularly for the more potent compounds. Remarkable progress has been made in increasing the potency of bisphosphonates as inhibitors of bone resorption, and the most potent compounds in current use are characterized by the presence of a nitrogen atom at critical positions in the side chain which, together with the bisphosphonate moiety itself, seems to be essential for maximal activity. As a class the bisphosphonates offer a very effective means of treating Paget's disease.

Citing Articles

[Influencing fracture healing by specific osteoporosis medications].

Stumpf U, Schmidmaier R, Taipaleenmaki H, Bocker W, Kurth A, Hesse E Z Rheumatol. 2025; 84(2):107-112.

PMID: 39806104 DOI: 10.1007/s00393-024-01610-y.


A 2,7-dichlorofluorescein derivative to monitor microcalcifications.

Tholen P, Brown C, Keil C, Bayir A, Zeng H, Haase H Mol Syst Des Eng. 2023; 7(11):1415-1421.

PMID: 37927331 PMC: 10624163. DOI: 10.1039/d2me00185c.


Case Report and Literature Review: Bisphosphonate, Sirolimus, and Atenolol Treatment in a 4-Year-Old Child Diagnosed with Gorham-Stout Disease.

Park S, Yoo J, Ahn M Pharmaceuticals (Basel). 2023; 16(10).

PMID: 37895975 PMC: 10610495. DOI: 10.3390/ph16101504.


Targeting Agents in Biomaterial-Mediated Bone Regeneration.

Gisbert-Garzaran M, Gomez-Cerezo M, Vallet-Regi M Int J Mol Sci. 2023; 24(3).

PMID: 36768328 PMC: 9916506. DOI: 10.3390/ijms24032007.


The Rationale for Using Neridronate in Musculoskeletal Disorders: From Metabolic Bone Diseases to Musculoskeletal Pain.

Iolascon G, Moretti A Int J Mol Sci. 2022; 23(13).

PMID: 35805927 PMC: 9267106. DOI: 10.3390/ijms23136921.